BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10810363)

  • 1. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1.
    Sato N; Mizumoto K; Maehara N; Kusumoto M; Nishio S; Urashima T; Ogawa T; Tanaka M
    Anticancer Res; 2000; 20(2A):837-42. PubMed ID: 10810363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
    Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
    J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line.
    Zhang Y; Fujita N; Tsuruo T
    Int J Cancer; 1999 Dec; 83(6):790-7. PubMed ID: 10597196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
    Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
    Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
    DeHaan RD; Yazlovitskaya EM; Persons DL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):383-8. PubMed ID: 11761456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis.
    Kondo S; Barna BP; Kondo Y; Tanaka Y; Casey G; Liu J; Morimura T; Kaakaji R; Peterson JW; Werbel B; Barnett GH
    Oncogene; 1996 Sep; 13(6):1279-85. PubMed ID: 8808702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p21waf1/Cip1, MDM2 and p53 in vivo: analysis of cytological preparations.
    Dowell SP; McGoogan E; Picksley SM; el-Deiry WS; Vogelstein B; Hall PA
    Cytopathology; 1996 Oct; 7(5):340-51. PubMed ID: 8911758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
    Liu W; Zhang R
    Int J Oncol; 1998 Apr; 12(4):793-804. PubMed ID: 9499438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?
    Naumann U; Durka S; Weller M
    Oncogene; 1998 Sep; 17(12):1567-75. PubMed ID: 9794234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of cyclin G1 and p21WAF1/CIP1 in neurons following transient forebrain ischemia: comparison with early DNA damage.
    van Lookeren Campagne M; Gill R
    J Neurosci Res; 1998 Aug; 53(3):279-96. PubMed ID: 9698156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53.
    Fang L; Igarashi M; Leung J; Sugrue MM; Lee SW; Aaronson SA
    Oncogene; 1999 May; 18(18):2789-97. PubMed ID: 10362249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
    Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F9 embryonal carcinoma cells fail to stop at G1/S boundary of the cell cycle after gamma-irradiation due to p21WAF1/CIP1 degradation.
    Malashicheva AB; Kislyakova TV; Aksenov ND; Osipov KA; Pospelov VA
    Oncogene; 2000 Aug; 19(34):3858-65. PubMed ID: 10951579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288).
    Meng LH; Kohn KW; Pommier Y
    Oncogene; 2007 Jul; 26(33):4806-16. PubMed ID: 17297446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil.
    Johnson KR; Fan W
    Anticancer Res; 2002; 22(6A):3197-204. PubMed ID: 12530065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H; Nan L; Yu D; Agrawal S; Zhang R
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.